Expression of SMARCA2 and SMARCA4 in gastric adenocarcinoma and construction of a nomogram prognostic model
- PMID: 37634210
- DOI: 10.1007/s10147-023-02403-0
Expression of SMARCA2 and SMARCA4 in gastric adenocarcinoma and construction of a nomogram prognostic model
Abstract
Background: Aberrant expression of SWI/SNF complex subunits is closely associated with tumorigenesis. The clinicopathological and prognostic significance of altered SMARCA2 and SMARCA4 subunits has not been well evaluated in gastric adenocarcinoma.
Methods: We collected 1271 postoperative cases of gastric adenocarcinoma and then constructed tissue microarrays (TMA), from which we obtained the immunohistochemistry expression of SMARCA2 and SMARCA4. Next, we screened the variables related to the loss of SMARCA2 and SMARCA4 by univariate correlation analysis and multivariate logistic regression analysis. Then, we identified the variables related to prognosis by univariate and multivariate Cox regression analysis. Finally, we constructed a nomogram prognostic model and evaluated it.
Results: The loss of SMARCA2 and SMARCA4 occurred in 236 (18.57%) and 86 (6.77%) cases, respectively, including 26 cases of co-loss. After multivariate logistic regression, variables independently associated with SMARCA2 loss were T stage, differentiation status, WHO histological classification, and EBER. Variables independently associated with SMARCA4 loss were differentiation status, WHO histological classification, PD-L1, and MMR. Survival analysis revealed that the SMARCA2 and SMARCA4 lost groups showed worse survival than the corresponding present groups (P = 0.032 and P = 0.0048, respectively). Univariate and multivariate Cox analyses identified independent prognostic factors, including age, T stage, N stage, M stage, SMARCA2, and chemotherapy.
Conclusion: The loss of SMARCA2 and SMARCA4 correlated with poor differentiation, leading to a worse prognosis. SMARCA2, as an independent prognostic factor, combined with other clinicopathological variables, established a novel nomogram prognostic model, which outperformed the AJCC TNM model.
Keywords: Gastric adenocarcinoma; Nomogram; Prognosis; SMARCA2; SMARCA4.
© 2023. The Author(s) under exclusive licence to Japan Society of Clinical Oncology.
Similar articles
-
Clinicopathological and prognostic significance of SWI/SNF complex subunits in undifferentiated gastric carcinoma.World J Surg Oncol. 2022 Dec 4;20(1):383. doi: 10.1186/s12957-022-02847-0. World J Surg Oncol. 2022. PMID: 36464671 Free PMC article.
-
Switch/sucrose-non-fermentable (SWI/SNF) complex (SMARCA4, SMARCA2, INI1/SMARCB1)-deficient colorectal carcinomas are strongly associated with microsatellite instability: an incidence study in 4508 colorectal carcinomas.Histopathology. 2022 May;80(6):906-921. doi: 10.1111/his.14612. Epub 2022 Feb 24. Histopathology. 2022. PMID: 34951482
-
SWI/SNF Complex-deficient Undifferentiated/Rhabdoid Carcinomas of the Gastrointestinal Tract: A Series of 13 Cases Highlighting Mutually Exclusive Loss of SMARCA4 and SMARCA2 and Frequent Co-inactivation of SMARCB1 and SMARCA2.Am J Surg Pathol. 2016 Apr;40(4):544-53. doi: 10.1097/PAS.0000000000000554. Am J Surg Pathol. 2016. PMID: 26551623
-
[Clinicopathological features of gastric alpha-fetoprotein-producing adenocarcinoma with SWI/SNF complex deletion].Zhonghua Bing Li Xue Za Zhi. 2024 Jan 8;53(1):52-57. doi: 10.3760/cma.j.cn112151-20231023-00284. Zhonghua Bing Li Xue Za Zhi. 2024. PMID: 38178747 Review. Chinese.
-
Synthetic lethality: targeting SMARCA2 ATPase in SMARCA4-deficient tumors - a review of patent literature from 2019-30 June 2023.Expert Opin Ther Pat. 2024 Mar;34(3):159-169. doi: 10.1080/13543776.2024.2338111. Epub 2024 Apr 5. Expert Opin Ther Pat. 2024. PMID: 38578210 Review.
Cited by
-
SMARCA4-deficient undifferentiated gastric carcinoma: a case series and literature review.Gastric Cancer. 2024 Sep;27(5):1147-1152. doi: 10.1007/s10120-024-01510-9. Epub 2024 May 22. Gastric Cancer. 2024. PMID: 38772975 Review.
-
Aberrant SWI/SNF Complex Members Are Predominant in Rare Ovarian Malignancies-Therapeutic Vulnerabilities in Treatment-Resistant Subtypes.Cancers (Basel). 2024 Sep 3;16(17):3068. doi: 10.3390/cancers16173068. Cancers (Basel). 2024. PMID: 39272926 Free PMC article. Review.
-
SWItch/Sucrose Nonfermentable complex-deficient pulmonary neoplasms: clinicopathologic characteristics and outcomes to radiotherapy and immunotherapy.Transl Lung Cancer Res. 2024 Oct 31;13(10):2660-2672. doi: 10.21037/tlcr-24-339. Epub 2024 Oct 28. Transl Lung Cancer Res. 2024. PMID: 39507018 Free PMC article.
-
SMARCA4 Mutations in Gastroesophageal Adenocarcinoma: An Observational Study via a Next-Generation Sequencing Panel.Cancers (Basel). 2024 Mar 27;16(7):1300. doi: 10.3390/cancers16071300. Cancers (Basel). 2024. PMID: 38610978 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous